The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with advanced solid tumors (advanced cancer)
Patient's disease must be evaluable using the RECIST criteria
Patients must be 18 or older in Korea or 20 or older in Japan
Patients must be relatively healthy as measured by their performance status
Patients must have acceptable laboratory values as measured by blood tests
Patients must be able to swallow capsules
Patients must understand the study and give written permission to enter study
Patients cannot have brain tumors
Patients cannot have had prior medicines that are similar to the study drug or an HDAC inhibitor medicine
Patients must not be classified as a "poor or intermediate CYP2C9 metabolizer" as measured using a sample of their blood
Patients must have recovered from all previous anti-cancer therapy
Patients must have finished taking their previous anti-cancer therapy before entering study
Patients must not have a severe disease at the time of study entry (for example: severe diarrhea, disease of the liver or kidney, other cancers, etc.)
Patients must have relatively good heart function
Other protocol-defined inclusion/exclusion criteria may apply